logo-loader
viewVyome Therapeutics Inc.

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of...

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California. Bunka telling Proactive...

16 hours, 49 minutes ago

2 min read